3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
Rituximab
47
Cyclophosphamide
45
fludarabine
22
Filgrastim
21
Lenalidomide
18
fludarabine phosphate
17
Prednisone
16
Radiotherapy
15
Peripheral Blood Stem Cell Transplantation
15
Etoposide
15
Vincristine
14
Doxorubicin
14
Melphalan
13
Busulfan
13
pembrolizumab
11
Tacrolimus
11
Methotrexate
10
Gemcitabine
10
ibrutinib
9
Bendamustine Hydrochloride
9
Alemtuzumab
9
obinutuzumab
8
Bortezomib
8
Vorinostat
7
Mycophenolic Acid
7
Granulocyte Colony-Stimulating Factor
7
Carboplatin
7
Azacitidine
7
venetoclax
6
Whole-Body Irradiation
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts